How well does Bavencio(Avelumab) work?

Clinical trials demonstrated durable tumor responses and improved survival outcomes in the indicated cancers.

Clinical Trial Outcomes

Efficacy was established in multiple trials. In metastatic MCC, the confirmed overall response rate was 33% in previously treated patients and 40% in treatment-naïve patients, with many responses lasting six months or longer. For UC maintenance therapy, BAVENCIO plus best supportive care significantly improved overall survival compared to best supportive care alone. In advanced RCC, the combination with axitinib significantly improved progression-free survival and the objective response rate compared to sunitinib in the first-line setting, demonstrating substantial clinical benefit.